ClinicalTrials.gg
CompletedNCT05217199highriskUpdated Nov 29, 2023

The Prechtl's General Movement Assessment, Hammersmith Infant Neurological Examination and Sensory Profile-2

An observational study in Infant Development, Sensory Disorder and Sensory Processing Disorder, sponsored by Kahramanmaras Sutcu Imam University. Completed at 1 site in Turkey. Open to participants aged 25 Weeks to 42 Weeks, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-11-29.

Sponsored by Kahramanmaras Sutcu Imam University · Observational

Study type
Observational
Model
Case-control
Time perspective
Retrospective
Enrollment
34
Ages
25 Weeks to 42 Weeks
Sex
All
01

Study summary

In the Neonatal Intensive Care Unit (NICU), infants encounter many sensory stimuli (excessive noise, bright lights, painful medical applications, etc.) that are not present in the uterus. During the critical period of brain development, this sensory overload affects the physiological responses of infants; It can lead to sensory processing problems by causing negative changes in motor, neurological and sensory development. Sensory processing was explained by Dunn as the emergence of appropriate reactions and behaviors in neurological processes in which visual, auditory, tactile, oral, olfactory, vestibular, proprioceptive and kinesthetic inputs are regulated.

Read the detailed description

There are interactions between an individual's neurological thresholds and emotional and behavioral responses or self-regulation strategies. Sensory modulation is an active processing process in which the brain adapts to sensory inputs from the environment by stimulating or inhibiting neurons as required by the current situation. Based on the interaction between an individual's neurological threshold and behavioral responses, Dunn developed four different response categories. These are sensation seeking, avoidance, low registration, and increased sensory sensitivity. From infancy, these processes show appropriate development with natural stimuli. However, sometimes there may be deviations in development from early infancy. One of them is the NICU, which is necessary to support vital functions. Decreased spontaneous movements for any reason and exposure to excessive sensory stimuli in this environment may cause negative consequences for the normal sensory and motor development of the baby.Babies who stay in the NICU for a long time stay away from natural sensory stimuli. Newborn preterm infants receive less tactile and vestibular stimulation in the NICU than does prenatal maternal movement. However, they are exposed to increased stimulus with other negative stimuli such as bright lights, high noise levels, excessive use and frequent painful interventions, which are not found in the intrauterine environment in the NICU. This can have lasting effects on the developing brain and affect the natural development of sensory systems. In the studies conducted, a significant difference was found between term babies and preterm babies in terms of sensory profile scores. Studies examining the relationship between sensory processing parameters and motor development in infants are limited in the literature. There is also a need for studies examining the relationship between sensory-motor development from the neonatal period. It is thought that preterm infants are exposed to these negative sensory stimuli longer. Neurodevelopmental follow-up is required after discharge in these infants with biological sensitivity and risk of neurological injury.The aim of this study is to examine the motor and sensory development of high-risk infants and compare them with their peers.

02

Conditions studied

  • Infant Development
  • Sensory Disorder
  • Sensory Processing Disorder
  • Motor Delay
  • Infant, Premature, Diseases
  • Infant, Very Low Birth Weight
  • Infant Asphyxia
  • Development Delay

Keywords

  • Motor development
  • Sensory development
  • High risk of Infants
  • Sensry disorder
03

In context

Sensation Disorders

87 studies on the registry are indexed under Sensation Disorders; 23 are open to participants now.

This study's enrollment of 34 is below the median of 58 across 25 observational studies indexed under Sensation Disorders.

Browse Sensation Disorders studies →

Lead sponsor

Kahramanmaras Sutcu Imam University is the lead sponsor of 198 studies on the registry; 40 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
25 Weeks to 42 Weeks
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

High risk of infants and healty peer aged control group

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Term preterm babies with 0-3 months of prenatal, postnatal and natal risk who stayed in the NICU for >2 weeks for any reason and were corrected after discharge
  • Babies with periventricular bleeding, ICH stage 2, 3, 4, cystic PVL, stage 3 HIE, neonatal encephalopathy (kernicterius), perinatal stroke, perinatal asphyxia, hydrocephalus
  • Babies with chronic lung disease, RDS, BPD and long-term Oxygen support (≥7 days)
  • Preterm infants with gram-negative bacteria-associated sepsis, Necrotizing Enterocolitis (NEC), infantile apnea, cerebral malformation
  • Preterm babies with low 5th minute Apgar score (3 and below), diagnosed with intrauterine growth retardation, multiple births (twins, triplets), PR
  • Infants with prolonged severe hypoglycemia and hypocalcemia
  • Surgical conditions such as diaphragmatic hernia or tracheoesophageal fistula
  • Babies who are small for gestational age (GYB, less than 3rd percentile) or large for gestational age (GYB, greater than 97th percentile)
  • Babies who are MV dependent for more than 24 hours
  • Babies born less than 32 weeks of gestation and weighing less than 1500 g
  • Healthy term babies

Exclusion criteria

Exclusion Criteria:

    • Babies of parents who did not agree to participate in the study/Babies who did not attend follow-up evaluations
  • Babies with congenital malformations (Spina Bifida, Congenital Muscular Torticollis, Arthrogryposis Multiplex Congenita)
  • Babies diagnosed with metabolic and genetic diseases (Down Syndrome, Spinal Muscular Atrophy, Duchenne Muscular Dystrophy.)
  • Babies who are still intubated and dependent on MV at postterm 3 months
  • Babies with hearing and vision loss
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Observational model
Case-control
Time perspective
Retrospective
Enrollment
34 participants (actual)
Patient registry
No

Groups and cohorts

  • 1/high risk of infants for cp

    1/ high risk of infants for cp was evaulated.

    Other: Measurements

Interventions

  • OtherMeasurements

    Demographic information of infants and parents, prenatal, postnatal and natal risk factors, Magnetic Resonance Images (MRI), General Movements (GMs) evaluations of babies with Prechtl method from NICU will be recorded. Video recordings for General Movements (GMs) analyzes with the Prechtl method will be taken at postterm 12th to 20th weeks. The infants' sensory processing (general, auditory, visual, tactile, movement, oral) will be evaluated with the adjusted Infant Sensory Profile-2 (ISP-2) family scale, which will be filled in by their mothers at the 3rd month. For motor assessments, the postterm corrected 3 month Hammersmith Infant Neurological Examination (HINE) will be used. A pediatric neurologist who was blinded to all testing made the diagnosis of CP in a 2-year-old child based on neuroimaging and clinical tests.

06

What researchers measure

Primary outcomes

  1. Infant Sensory Profile-2 (ISP-2)

    The Infant Sensory Profile (ISP-2) questionnaire is a 24-item questionnaire consisting of sensory profile general sensory processing score, auditory processing, visual processing score, tactile processing, motion processing, oral sensory processing sub-scores. The sensory profile raw score total score is calculated with the sum of the sub-scores. Higher scores shows better sensory functions.

    Time frame: one assessment at the corrected age of 3th months.

  2. Hammersmith Infant Neurological Examination (HINE)

    The HINE is a simple, standardized, and scorable test for the clinical neurological evaluation of 2-to-24-month-old infants. It has 3 sections: (1) neurological examination (26 items, scored) evaluating cranial nerve function, posture, movements, tone, reflexes, and reactions, (2) motor milestones (8 items, unscored), and (3) behaviour (3 items, unscored). Each of the 26 items is scored first separately (as 0, 1, 2, or 3, half scores) and then the total score is calculated with a maximum score of 78. Higher score indicates good neurological function.

    Time frame: one assessment at postterm corrected age of 3th months.

  3. Prechtl's General Movements Assessments (GMs)1

    General movements (GMs) are the spontaneous movement repertoire present from early foetal life until 20 weeks post-term. From birth to 8 post-term weeks, they have a "writhing" character. They will be scored as cs-pr-n-ch. From 12th to 20th weeks, they have "fidgety" character.

    Time frame: Measurement at postterm age of 12tk to 20th weeks.

  4. Diagnosis of CP (neuroimaging by MRI)

    Based on neuroimaging and clinical evaluations at 2 years of age, a pediatric neurologist who was blinded to all assessments diagnosed CP. The neuroimaging scans were classified into one of seven primary patterns of abnormality as defined and described by

    Time frame: Measurement once at 2 years of age

07

Study locations

1 site
  • Hatice Adıgüzel
    Kahramanmaras, Dulkadiroglu 46100, Turkey
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2022 to primary completion in Jul 2023, 15 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 5, 2022
First posted
Feb 1, 2022
StartActual
Apr 15, 2022
Primary completionActual
Jul 15, 2023
CompletionActual
Aug 15, 2023
Last update
Nov 29, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 29, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05217199
Responsible party
Hatice Adiguzel (Assistant Proffessor, Kahramanmaras Sutcu Imam University) — Principal investigator
First posted
Feb 1, 2022
Start date
Apr 15, 2022
Primary completion
Jul 15, 2023
Completion
Aug 15, 2023
Last update
Nov 29, 2023

Study contacts

hatice adıgüzel, PhD
principal investigator · Kahramanmaras Sutcu Imam University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion